Views: 955 Author: Site Editor Publish Time: 2026-06-30 Origin: Site
The Quiet Shift Happening in Ophthalmic Formulation Labs
If you walked through the formulation R&D floor of any major ophthalmic company a decade ago, polyvinyl alcohol (PVA) was almost a default. It was cheap, it was on the FDA demulcent list, it had a long regulatory track record, and it worked. Today, walk through the same labs, and you'll notice something different: hyaluronic acid (HA) — specifically sodium hyaluronate — has quietly become the polymer of choice for new artificial tear development.
The numbers back this up. In China alone, the prescription-grade sodium hyaluronate eye drop market reached 23 billion RMB in 2025, growing at 15% year-on-year. Hyaluronic-acid-containing products now account for 64.3% of all artificial tear prescriptions, up from 61.1% a year earlier. Meanwhile, single-dose preservative-free formulations — almost all HA-based — climbed from 42.6% to 47.9% of the market in just twelve months.
This isn't a marketing fad. It's a formulation shift driven by mechanism, clinical evidence, and changing regulatory expectations. If you're an R&D lead, a procurement manager, or a regulatory affairs specialist evaluating which polymer to anchor your next artificial tear formulation around, the HA-vs-PVA decision is no longer a default choice. It's a strategic one. This guide walks through what actually drives that decision.
The first mistake we see in formulation reviews is treating PVA and HA as interchangeable lubricants. They're not.
Polyvinyl alcohol is a synthetic water-soluble polymer. It earned its place on the FDA's 1988 OTC demulcent monograph because it does one thing reliably: it increases tear film viscosity, slows tear evaporation, and provides immediate mechanical lubrication when instilled. It's a passive polymer — it sits on the ocular surface, retains moisture, and gets blinked away. Simple, predictable, cheap.
Hyaluronic acid is biologically active. It's a naturally occurring glycosaminoglycan found in human vitreous, aqueous humor, cornea, and the tear film itself. When you instill sodium hyaluronate onto a dry, inflamed ocular surface, you don't just get lubrication. You get:
· Mechanical lubrication through its viscoelastic properties
· Water retention at roughly 1,000× its own weight, creating a slow-release reservoir of hydration
· CD44 receptor binding on corneal and conjunctival epithelium — the CD44 receptor is overexpressed in dry eye disease, and HA's binding promotes epithelial cell migration and re-epithelialization
· Anti-inflammatory action, particularly with high-molecular-weight HA, which has been shown to be protective against corneal cell apoptosis from benzalkonium chloride toxicity, UV radiation, and chemical burns
· Goblet cell stimulation, supporting the eye's native mucin production
That's a four-mode mechanism versus PVA's one. For mild transient dryness, the difference may not matter clinically. For moderate-to-severe dry eye disease (DED), post-surgical patients, or cases involving corneal epithelial damage, the gap is significant.
This is where the literature gets interesting — and where some marketing claims overreach.
A systematic review of 18 clinical studies comparing sodium hyaluronate against non-HA artificial tears (including PVA) found that the majority of datasets showed HA superiority on ocular staining outcomes, with most reaching statistical significance. HA outperformed every control category tested — vehicle, PVA, normal saline, cellulose derivatives, and carbomer-based eyedrops.
A separate 2023 systematic review of 64 RCTs (published in Clinical Ophthalmology) drew several conclusions directly relevant to formulators:
· High molecular weight HA is clinically superior to its low molecular weight counterpart in DED treatment
· Combination formulations consistently outperform single-active-ingredient artificial tears
· Cationic formulations outperform PVA for objective dry eye signs
· Carbomer-based drops may outperform PVA for symptom relief
However — and this is important — the same review noted that for Schirmer's test and tear film breakup time (TBUT), the difference between HA and non-HA preparations was not always clinically significant in head-to-head trials. The story is more nuanced than "HA wins everything."
Where PVA continues to hold ground:
· Immediate symptomatic relief in mild dry eye, where low viscosity matters more than mechanism
· Blur-free experience, since higher-concentration HA (≥0.2%) can cause transient visual blurring
· Cost-sensitive markets, where unit economics drive procurement decisions
· Contact lens rewetting, where PVA's lower bioadhesion is actually an advantage
The honest read of the literature: HA is the better choice for most indications, but PVA still has a defensible role. Formulators need to choose based on indication, not ideology.
When we work with ophthalmic formulation teams, the decision usually comes down to five variables. Working through them in order gives you a defensible specification.
Indication | Polymer Recommendation |
Mild transient dryness (digital eye strain, occasional dryness) | PVA acceptable; HA optional |
Moderate DED (BUT < 10s, daily symptoms) | HA preferred, 0.1–0.18% |
Severe DED (BUT < 5s, corneal staining) | HA strongly preferred, 0.2–0.4%, ideally HMW |
Post-surgical (cataract, LASIK, corneal procedures) | HA only, for wound healing properties |
Corneal epithelial damage / persistent epithelial defect | HA only, often combined with other actives |
Higher viscosity means longer ocular residence time but more transient blur. PVA solutions are typically lower-viscosity and faster-clearing. HA viscosity scales with molecular weight and concentration — a 0.1% HA at 800 kDa behaves very differently from 0.3% HA at 1.5 MDa. If your target user profile cannot tolerate even brief blur (drivers, machinery operators, those instilling drops during meetings), lower-viscosity HA grades or PVA may be appropriate.
The regulatory and clinical pressure on benzalkonium chloride and other traditional preservatives has accelerated dramatically. If you're targeting preservative-free single-dose unit-dose vials — which now dominate new launches in the EU, Japan, and increasingly China — HA's biocompatibility makes it the natural fit. PVA in single-dose preservative-free format works but offers no inherent advantage over HA, while costing roughly the same in unit economics at scale.
PVA has historically had an edge for contact-lens-friendly artificial tears because its lower bioadhesion means less buildup on the lens surface. However, lower-molecular-weight HA grades (typically <500 kDa) are now demonstrating excellent contact lens compatibility while retaining biological benefits. This advantage gap has narrowed substantially in the last five years.
Raw material cost is real. Pharmaceutical-grade sodium hyaluronate at the molecular weight and endotoxin specifications required for ophthalmic formulation typically prices at 5–10× cosmetic-grade HA and 3–6× PVA per kilogram. For OTC products competing on shelf price, this matters. For prescription products, premium DED therapies, and post-surgical rewetting, the raw material cost is a negligible fraction of unit revenue.
Here's the part of the formulation decision that's invisible from the outside but determines whether your final product passes stability testing, regulatory review, and clinical performance.
A "sodium hyaluronate" specification on a COA can mean very different products depending on the supplier. For ophthalmic-grade material, four quality dimensions matter:
Molecular weight distribution. Pharmaceutical-grade HA for eye drops typically falls in the 800,000 to 1,500,000 Dalton band, with controlled polydispersity. A wide distribution will give inconsistent viscosity batch-to-batch — a nightmare for QC release. High-MW grades (>1 MDa) deliver the anti-inflammatory and protective properties documented in clinical trials.
Endotoxin limits. The gap between cosmetic-grade and ophthalmic-grade HA is most visible here. Cosmetic-grade HA tolerates endotoxin up to 50 EU/mg. Ophthalmic-grade material must meet ≤0.5 EU/mg — a hundredfold tighter specification. This requires segregated fermentation lines, validated purification, and rigorous in-process testing.
Protein residue. ≤0.1% is the pharmaceutical baseline. Higher residual protein from incomplete purification triggers immune responses on the ocular surface and accelerates stability failures.
Sterility & production environment. Single-dose preservative-free products require sodium hyaluronate produced under sterile or low-bioburden conditions, often with terminal sterilization compatibility. This is not a feature you can retrofit — it has to be built into the production line from the start.
PVA's specifications are simpler (it's a synthetic, well-characterized polymer), but the consequence is that PVA offers limited differentiation. With HA, the raw material itself becomes part of your product's competitive moat. Choose the right supplier and grade, and your formulation outperforms competitors using the same polymer.
If you're designing a product launch for 2027 or 2028, three trends will shape the landscape you're launching into:
Single-dose preservative-free will become the default for new launches. In China alone, this format moved from 42.6% to 47.9% market share in one year. In the EU and Japan, the share is already higher. HA's biocompatibility profile makes it the natural anchor for preservative-free formats.
High-molecular-weight HA will continue to gain ground. New product launches like EyePromise's Heyedrate Clinical (entering the US market with Hylan A, the highest-MW HA formulation available in the US) signal where premium positioning is heading. Clinical data on reduced drop frequency (27% reduction versus mid-MW competitors) gives HMW HA a real selling story for clinicians.
Combination formulations are the new frontier. HA + trehalose, HA + CMC, HA + osmoprotectants, HA + vitamin E — the literature now consistently shows that combination drops outperform single-actives. Even some new formulations strategically combine HA and PVA to capture both polymers' strengths. If you're formulating a single-active product today, you're already behind the trend.
Regulatory tightening favors biocompatible polymers. As regulators tighten safety expectations on preservatives, novel excipients, and animal-derived materials, fermentation-derived HA (non-animal, non-allergenic, fully traceable) becomes the lowest-risk choice for new product registrations.
We've made the case for HA for most modern formulations. But credible formulation guidance has to acknowledge where PVA still earns its place:
· Mass-market OTC dry eye products where shelf price is the dominant competitive lever
· Contact lens rewetting drops in cost-sensitive markets, particularly for daily-disposable wearers
· Generic OTC artificial tears designed for symptomatic relief of mild dryness in pharmacy private labels
· Combination drops that strategically use PVA for immediate lubrication alongside HA for biological action and longer ocular retention
· Established legacy formulations with strong brand equity and proven regulatory tracks — switching the active polymer isn't always justified
The point is not that PVA is obsolete. It's that PVA has narrowed into a specific set of use cases, while HA has expanded across the majority of new development. Choosing the right polymer means matching it to indication, target user, regulatory pathway, and price positioning — not defaulting to either one.
Whether your next artificial tear formulation lands on HA, PVA, or a combination, one thing doesn't change: raw material consistency is non-negotiable. The difference between a stable, clinically-performing eye drop and a recall-prone formulation often comes down to whether your supplier delivers within spec, batch after batch, year after year.
For HA specifically, the supplier choice carries unusual weight because the polymer's biological activity is so tightly coupled to molecular weight, endotoxin level, and production discipline. Cosmetic-grade HA in an ophthalmic formulation isn't just under-spec — it's a regulatory and patient-safety failure waiting to happen.
Shandong Runxin Biotechnology has focused exclusively on hyaluronic acid for 28 years, since 1998. Our pharmaceutical-grade sodium hyaluronate operates under DMF 036368, ISO 13485, and cGMP compliance, with multiple molecular weight grades (oligomeric, low, medium, and high MW) optimized for different ophthalmic applications. We've supported ophthalmic formulators across 34 countries with consistent batch quality, full traceability, and the technical service that pharmaceutical development demands.
If you're evaluating raw material partners for an artificial tear, ophthalmic gel, or post-surgical lubricant formulation, we'd welcome a technical conversation — including molecular weight selection guidance, COA review, sample shipments, and stability data tailored to your indication.
[Contact our ophthalmic formulation team →]
Sources cited: Sodium Hyaluronate in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-Analysis (PMC5567178); Artificial Tears: A Systematic Review (PMC9840372); Management of Dry Eye Disease with Artificial Tears Containing Hyaluronic Acid and Trehalose (PMC12990230); Categorization of Marketed Artificial Tear Formulations (PMC8003881); 2026 China Sodium Hyaluronate Ophthalmic Market Report; FDA OTC Demulcent Monograph (1988).
